Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished the day at $20.00. Traded volume was 219,904 million shares … Continue reading Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% … Continue reading New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the tiny biological machine inside every cell that runs along messenger … Continue reading Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)